Creating opportunities out of change: Avecia OligoMedicinesSM becomes part of the Nitto Denko Corporation
For over 15 years, Avecia OligoMedicinesSM has used technical expertise and extensiveexperience to establish its position as a leader in oligonucleotide contract manufacturing anddevelopment. As the nucleic acid therapeutic market continues to evolve, Avecia is excited toadvance with it, as a new member of the Nitto Denko Corporation. By embracing Nitto Denko’sphilosophy of welcoming change as an opportunity, and using innovative ideas and flexible solutions,Avecia is prepared to meet and exceed the current and future needs of the oligonucleotide market.
...
